How many Americans are on GLP-1
Roughly 10 to 15 million adults in the United States use GLP-1 receptor agonists, including both prescription drugs such as semaglutide and liraglutide and newer combinations and delivery formats. This represents about 3 to 5 percent of the adult population, with use concentrated among people with type 2 diabetes and, increasingly, adults living with obesity. Usage has grown rapidly since 2020, driven by newer, more convenient formulations, expanded indications, and heightened awareness through clinical guidelines and media coverage. The following sections define who uses these medications, how estimates are derived, and how use varies by age, geography, insurance coverage, and time period.
Common GLP-1 medications in the U.S.
What GLP-1 agonists are prescribed most often
GLP-1 agonists enhance glucose-dependent insulin release, suppress glucagon, slow gastric emptying, and promote satiation. In the U.S., commonly prescribed agents include semaglutide (tablets and injectable), liraglutide, dulaglutide, exenatide extended-release, and lixisenatide. Semaglutide, available under brand names such as Ozempic (injectable) and Rybelsus (oral), accounts for a substantial share of new prescriptions. Usage patterns shift with new approvals, dosing convenience, insurance formularies, and clinical guidance, making broad estimates necessarily approximate.
Prevalence estimates and definitions
How prevalence is measured and reported
Estimates of how many Americans are on GLP-1 agonists come from multiple sources, each with strengths and limitations. These include national prescription fill data from commercial and Medicare Part D plans, medical claims in large integrated health systems, and nationally representative surveys such as the National Health and Nutrition Examination Survey (NHANES), which can detect use through serologic or medication recall methods. Prevalence is usually expressed as the number of users per 1,000 adults or as a percentage of the total adult population. Key estimates vary by timeframe and data source, reflecting both increased prescribing and changes in regulatory approvals and reimbursement.
| Metric | Estimate or Range | Source Type and Context |
|---|---|---|
| Adult users in the U.S. | 10 million to 15 million | Commercial and Medicare Part D pharmacy claims, adjusted for overlap (approximate) |
| Share of U.S. adults | 3% to 5% | Derived from total adult population estimates (e.g., ~260 million adults) |
| Growth from 2020 to 2023 | Multiplication roughly 2–4x in many health system datasets | Claims and EHR data; varies by age group and indication (diabetes vs obesity) |
| Top age group among new users | 35–64 years | Commercial insurance and Medicaid claims analyses |
| Public program share | Significant portion covered under Medicare Part D or Medicaid in many regions | Plan data; varies widely by state |
Demographic and geographic patterns
Who is currently taking GLP-1 agonists
- Age: Use rises steeply from ages 35 to 64 and is uncommon among adolescents and young adults, though use in younger adults is increasing.
- Clinical indication: The majority of use is for type 2 diabetes; a growing share is for weight management in people with obesity, sometimes under brand names and medical supervision.
- Insurance: Coverage is common through employer-sponsored plans, Medicare Part D, and Medicaid, though prior authorization and formulary restrictions can affect accessibility.
- Geography: Prescription rates vary across regions and are influenced by local provider networks, hospital system adoption, and state-level policies on telehealth prescribing.
Drivers of recent growth
Clinical guidelines, media attention, and access channels
Several factors explain the rapid increase in GLP-1 use, including new medication approvals, stronger clinical recommendations for diabetes and obesity, and widespread media attention. Integration into weight management programs and telehealth prescribing have expanded access in some regions. At the same time, supply constraints, varying insurance policies, and differing clinical comfort levels mean adoption is uneven across practices and localities. Public debate about use for weight loss, cost, and long-term safety has also shaped awareness and patient demand.
Data limitations and what to watch
Challenges in measuring exact use and future trends
Because many sources aggregate GLP-1 medications with other diabetes drugs, it is difficult to isolate exact current usage without accessing proprietary pharmacy or health system datasets. Definitions of use (filled prescriptions, active users, regular users) can change how prevalence is reported. Future estimates will likely shift as new combination products enter the market, as payer policies evolve, and as long-term outcomes are studied. Public data such as NHANES medication modules and annual pharmacy snapshots will remain central for tracking trends.
Key takeaways
As of the most recent multiyear analyses, approximately 10 to 15 million U.S. adults are using GLP-1 agonists, corresponding to roughly 3 to 5 percent of the adult population. Use is concentrated among adults aged 35 to 64, particularly those with type 2 diabetes, and has grown substantially since 2020. Estimates vary by data source and definition, but all point to a substantial and rising share of the adult population on these medications. Ongoing shifts in approvals, coverage, and prescriber behavior will continue to influence how many Americans are on GLP-1 treatments over time.